Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Tiziana Life SciencesHarrow HealthOptiNoseMedicenna TherapeuticsCalithera Biosciences
SymbolNASDAQ:TLSANASDAQ:HROWNASDAQ:OPTNNASDAQ:MDNANASDAQ:CALA
Price Information
Current Price$2.67$7.05$3.52$4.06$2.35
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.41.60.71.7
Analysis Score3.53.53.33.53.4
Community Score2.32.12.40.02.8
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.70.01.7
Earnings & Valuation Score0.00.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$9.50$14.00$18.00$10.00$5.20
% Upside from Price Target255.81% upside98.58% upside411.36% upside146.31% upside121.28% upside
Trade Information
Market Cap$171.47 million$183.18 million$186.37 million$215.00 million$172.30 million
Beta1.411.081.031.391.77
Average Volume991,225226,594452,776217,6711,655,910
Sales & Book Value
Annual RevenueN/A$51.17 million$34.63 millionN/A$22.25 million
Price / SalesN/A3.585.38N/A7.74
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.09) per share$1.09 per share$1.48 per share$0.77 per share$2.24 per share
Price / BookN/A6.472.38N/A1.05
Profitability
Net Income$-9,320,000.00$170,000.00$-110,050,000.00$-6,220,000.00$-89,860,000.00
EPS($0.03)($0.29)($2.63)($0.19)($1.90)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/A25.18N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-3.94%-230.14%N/AN/A
Return on Equity (ROE)N/A-3.52%-294.64%-40.19%-66.64%
Return on Assets (ROA)N/A-1.36%-59.29%-37.66%-56.60%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.53%3.79%N/AN/A
Current Ratio1.86%2.97%3.98%26.75%7.07%
Quick RatioN/A2.68%3.76%26.75%7.07%
Ownership Information
Institutional Ownership PercentageN/A44.37%62.93%3.90%73.99%
Insider Ownership PercentageN/A12.43%38.00%N/A11.90%
Miscellaneous
Employees8133204790
Shares Outstanding64.22 million25.98 million52.95 million52.96 million73.32 million
Next Earnings Date6/16/2021 (Estimated)5/10/2021 (Estimated)5/6/2021 (Estimated)5/21/2021 (Estimated)5/6/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Could The Calithera Biosciences, Inc. (NASDAQ:CALA) Ownership Structure Tell Us Something Useful?Could The Calithera Biosciences, Inc. (NASDAQ:CALA) Ownership Structure Tell Us Something Useful?
nasdaq.com - April 9 at 11:05 PM
 Analysts Anticipate Calithera Biosciences, Inc. (NASDAQ:CALA) Will Announce Earnings of -$0.27 Per Share Analysts Anticipate Calithera Biosciences, Inc. (NASDAQ:CALA) Will Announce Earnings of -$0.27 Per Share
americanbankingnews.com - April 7 at 2:14 AM
Calithera Biosciences, Inc. (NASDAQ:CALA) Sees Significant Decline in Short InterestCalithera Biosciences, Inc. (NASDAQ:CALA) Sees Significant Decline in Short Interest
americanbankingnews.com - March 31 at 8:28 AM
Were Keeping An Eye On Calithera Biosciences (NASDAQ:CALA) Cash Burn RateWe're Keeping An Eye On Calithera Biosciences' (NASDAQ:CALA) Cash Burn Rate
finance.yahoo.com - March 29 at 8:59 AM
Calithera Biosciences Inc (CALA) Q4 2020 Earnings Call TranscriptCalithera Biosciences Inc (CALA) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 25 at 1:55 AM
Jefferies Financial Group Comments on Calithera Biosciences, Inc.s FY2021 Earnings (NASDAQ:CALA)Jefferies Financial Group Comments on Calithera Biosciences, Inc.'s FY2021 Earnings (NASDAQ:CALA)
americanbankingnews.com - March 22 at 1:58 AM
Zacks: Analysts Expect Calithera Biosciences, Inc. (NASDAQ:CALA) Will Announce Earnings of -$0.27 Per ShareZacks: Analysts Expect Calithera Biosciences, Inc. (NASDAQ:CALA) Will Announce Earnings of -$0.27 Per Share
americanbankingnews.com - March 20 at 6:12 PM
Q1 2021 Earnings Estimate for Calithera Biosciences, Inc. (NASDAQ:CALA) Issued By SVB LeerinkQ1 2021 Earnings Estimate for Calithera Biosciences, Inc. (NASDAQ:CALA) Issued By SVB Leerink
americanbankingnews.com - March 19 at 8:33 AM
Calithera Biosciences (NASDAQ:CALA) Stock Price Down 5.5%Calithera Biosciences (NASDAQ:CALA) Stock Price Down 5.5%
americanbankingnews.com - March 18 at 7:25 PM
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2020 Results - Earnings Call TranscriptCalithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 18 at 5:07 AM
Calithera Biosciences (NASDAQ:CALA) Posts Quarterly  Earnings Results, Hits ExpectationsCalithera Biosciences (NASDAQ:CALA) Posts Quarterly Earnings Results, Hits Expectations
americanbankingnews.com - March 17 at 8:10 AM
Calithera: Q4 Earnings SnapshotCalithera: Q4 Earnings Snapshot
sfgate.com - March 16 at 8:31 PM
Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent HighlightsCalithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights
finance.yahoo.com - March 16 at 8:31 PM
UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday,UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday,
apnews.com - March 12 at 3:50 PM
UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021
finance.yahoo.com - March 12 at 3:50 PM
Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021
finance.yahoo.com - March 10 at 7:29 AM
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 ConferenceCalithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference
finance.yahoo.com - March 2 at 7:15 AM
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceCalithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 22 at 9:15 AM
Calithera Biosciences, Inc. (NASDAQ:CALA) is an exciting stock to watchCalithera Biosciences, Inc. (NASDAQ:CALA) is an exciting stock to watch
stocksregister.com - February 7 at 7:28 AM
Implied Volatility Surging for Calithera Biosciences (CALA) Stock OptionsImplied Volatility Surging for Calithera Biosciences (CALA) Stock Options
finance.yahoo.com - January 13 at 2:49 PM
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal ...INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal ...
apnews.com - January 12 at 5:44 AM
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat FailsCalithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
finance.yahoo.com - January 5 at 1:29 PM
Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not ...Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not ...
apnews.com - January 5 at 8:29 AM
Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 ConferenceCalithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
finance.yahoo.com - January 5 at 8:29 AM
Why Is It Moving? Analyzing The Downward Movement in Calithera Biosciencess Stock TodayWhy Is It Moving? Analyzing The Downward Movement in Calithera Biosciences's Stock Today
msn.com - January 4 at 2:23 PM
DateCompanyBrokerageAction
12/22/2020Tiziana Life SciencesB. RileyInitiated Coverage
9/21/2020Tiziana Life SciencesHC WainwrightReiterated Rating
9/10/2019Tiziana Life SciencesLaidlawSet Price Target
8/16/2019Harrow HealthLake Street CapitalSet Price Target
7/16/2020OptiNosePiper SandlerReiterated Rating
7/16/2020OptiNoseRoyal Bank of CanadaReiterated Rating
3/5/2020OptiNoseCantor FitzgeraldLower Price Target
12/18/2019OptiNoseCowenInitiated Coverage
8/13/2019OptiNoseBMO Capital MarketsLower Price Target
4/23/2019OptiNosePiper Jaffray CompaniesSet Price Target
12/17/2020Medicenna TherapeuticsOppenheimerInitiated Coverage
8/24/2020Medicenna TherapeuticsBrookline Capital ManagementReiterated Rating
8/24/2020Medicenna TherapeuticsBloom BurtonReiterated Rating
1/5/2021Calithera BiosciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
1/5/2021Calithera BiosciencesSmith Barney CitigroupLower Price Target
1/5/2021Calithera BiosciencesSVB LeerinkDowngrade
6/2/2020Calithera BiosciencesWilliam BlairReiterated Rating
3/27/2020Calithera BiosciencesJefferies Financial GroupInitiated Coverage
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.